Innovative cryogenic system connector
technology designed to improve usability and maintain the integrity
of cryogen used in the cryoablation procedure
CAESAREA, Israel, Oct. 21,
2024 /PRNewswire/ -- IceCure Medical Ltd.
(Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"),
developer of minimally-invasive cryoablation technology that
destroys tumors by freezing as an alternative to surgical tumor
removal, today announced it has received a Notice of Allowance for
its invention titled "Cryogenic System Connector" from the U.S.
Patent and Trademark Office. This is the first global patent issued
for the cryogenic system connector, a key component of IceCure's
next-generation liquid nitrogen-based XSense™ cryoablation system.
Several other patent applications for this technology are pending
in key markets.
XSense™ and its cryoprobes, which have U.S. Food and Drug
Administration clearance for all of the indications for which
IceCure's flagship ProSense® has already received clearance, has
the potential to address additional indications and significant
unmet needs in the global tumor ablation market, estimated at
$1.67 billion in 2023 according
to Grand View Research.
"With a patent portfolio of over 50 issued patents and the
development of our next-generation systems, we continue to be an
innovation leader in the cryoablation space. We are committed to
fortifying our intellectual property assets as our cryoablation
systems gain commercial traction worldwide," stated IceCure's CEO,
Eyal Shamir.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets advanced
liquid-nitrogen-based cryoablation therapy systems for the
treatment of tumors (benign and cancerous) by freezing, with the
primary focus areas being breast, kidney, bone and lung cancer. Its
minimally invasive technology is a safe and effective alternative
to hospital surgical tumor removal that is easily performed in a
relatively short procedure. The Company's flagship ProSense® system
is marketed and sold worldwide for the indications cleared and
approved to date including in the U.S., Europe and China.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. Words such as "expects," "anticipates," "intends,"
"plans," "believes," "seeks," "estimates" and similar expressions
or variations of such words are intended to identify
forward-looking statements. For example, IceCure is using forward
looking statements in this press release when it discusses: the
potential for the Company's products to address additional
indications and significant unmet needs in the global tumor
ablation market; and the Company's commitment to fortifying its
intellectual property assets as its cryoablation systems gain
commercial traction worldwide. Historical results of scientific
research and clinical and preclinical trials do not guarantee that
the conclusions of future research or trials will suggest identical
or even similar conclusions. Important factors that could cause
actual results, developments and business decisions to differ
materially from those anticipated in these forward-looking
statements include, among others: the Company's planned level of
revenues and capital expenditures; the Company's available cash and
its ability to obtain additional funding; the Company's ability to
market and sell its products; legal and regulatory developments in
the United States and other
countries; the Company's ability to maintain its relationships with
suppliers, distributors and other partners; the Company's ability
to maintain or protect the validity of its patents and other
intellectual property; the Company's ability to expose and educate
medical professionals about its products; political, economic and
military instability in the Middle
East, specifically in Israel; as well as those factors set forth in
the Risk Factors section of the Company's Annual Report on Form
20-F for the year ended December 31,
2023 filed with the SEC on April 3,
2024, and other documents filed with or furnished to the SEC
which are available on the SEC's website, www.sec.gov. The Company
undertakes no obligation to update these statements for revisions
or changes after the date of this release, except as required by
law.
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo -
https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/icecure-receives-notice-of-allowance-from-us-patent-and-trademark-office-for-its-next-generation-cryoablation-system-302281638.html
SOURCE IceCure Medical
